Sonoma Pharmaceuticals lists facial spray under FDA’s MoCRA

Sonoma Pharmaceuticals (SNOA) registered its manufacturing facility and listed its Microcyn-based facial spray under the FDA’s Modernization of Cosmetics Regulation Act of 2022. The MoCRA registration expands Sonoma’s regulatory footprint, enabling the Company to manufacture and commercialize Microcyn technology products as cosmetics in the United States. Sonoma’s manufacturing facility is already FDA-registered as a medical device establishment, supporting Sonoma’s portfolio of FDA 510(k)-cleared products across wound care, dermatology, eye care, podiatry, and animal health. The MoCRA registration builds on this foundation and provides Sonoma with increased access to the rapidly growing U.S. cosmetics and dermatology consumer markets.